Controlled Clinical Observation Of Compound Huangdai Tablet In The Intensive Therapy Of Acute Promyelocytic Leukemia

BackgroundWith the development of genetics and molecular biology, people have a growing knowledge of Acute Promyelocytic Leukemia (APL) and thus the treatment for APL has become a hot research topic. Since the early1980s, the appearance of molecular targeting therapy All-trans Retinoic Acid (ATRA) has made the remission rate of APL over90%and the cure rate over70%. In this way, APL has transformed from a deadly disease into a acute myeloid disease with a promising treatment prospect. Arsenical is a kind of compound which comes from the traditional Chinese medicine;It has been employed in the theraphy of leukaemia by the western scholars since the19th century. From the1970s to1990s, by continuously reviewing the clinical effects, Chinese clinicians found that Arsenicals can induce cell differentiation and thus the remission rate of APL reached about80%. Afterwards, Chen Zhu and Wang Zhengyi, in the sense of Cellular and Molecular Biology.illustrate its mechanism, making Arsenicals accepted and used widely all over the world. Recent research shows that Arsenicals, combined with retinoids or used alone as the first-line therapy, can make the APL patients gain long-term remission; and it also makes it possible for reduceing trentment-related toxicity.The functions Arsenicals have made during the treatment of APL make the research of Chinese Compound arsenic preparations which is represented by Compound Huangdai Tablet(CHDT) during the remission treatment ofAPL, especially the application in the intensive treatment after the complete remission (CR) more significant. Besides,it offers a new approach to change the leukemia treatment situation that mainly conducted by western medicine and supplemented with traditional Chinese medicine.Purpose Based on the clinical comparative observation of CHDT in the intensive therpy of APL, we will do some further research about the true curative effect of Chinese Compound arsenic preparations in preventing recurrence, improving the LTDFS and reducing side effects.MethodCollect the dates of25APL patients who were treated in The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine during February2011to March2012. I’ll Dividing them into two groups according to radomized, single blind and parallel controlled methods(CHDT combination chemotherapy group and ATRA combination chemotherapy group). After the patients taking the medicine, do statistical analysis of hemogram, bone marrow,gene, liver and kidney function, clinical symptoms and toxic effects during the treatment process.ResultThrough comparative observation, we figure out there is no significant different treatment effects between the two groups (p>0.05); however, as for the toxic effects, CHDT combination chemotherapy group is much lower than ATRA combination chemotherapy group(p<0.05).ConclusionDuring the intensive therapy of APL, the treatment effects of CHDT is effective and practical,which is worth to promote.